Skip to main content
. 2018 Sep 28;9(76):34306–34319. doi: 10.18632/oncotarget.26142

Figure 3. Re-localization to the plasma membrane restores oncogenic activity to NLS-FGFR3-TACC3.

Figure 3

(A) Schematic of FGFR3-TACC3, NLS-FGFR3-TACC3 and Myr-NLS-FGFR3-TACC3 fusion proteins. NLS-FGFR3-TACC3 is the same fusion construct described in Fig. 1A. For the Myr-NLS derivative, the c-Src Myr sequence is fused in front of the NLS-FGFR3-TACC3 (Myr-NLS-FGFR3-TACC3). (B) Representative confocal micrographs of NIH3T3 cells stably expressing the indicated constructs, using FGFR3 immunostaining (P-18). Secondary antibodies were donkey anti-goat AlexFluor488 or donkey anti-goat AlexaFluor594. Nucleus is visualized with Hoechst 33342. (C) Transformation of NIH3T3 cells by the indicated constructs. Number of foci were scored, normalized by transfection efficiency, and quantitated relative to FGFR3-TACC3 ± SEM. Assays were performed a minimum of three times per DNA construct. (D) HEK293T cell lysates expressing FGFR3 or FGFR3-TACC3 derivatives were immunoblotted for phospho-MAPK (T202/Y204; top), MAPK (second panel) and FGFR3 (bottom).